| Literature DB >> 17537538 |
Seiji Niho1, Hirofumi Fujii, Koji Murakami, Seisuke Nagase, Kiyotaka Yoh, Koichi Goto, Hironobu Ohmatsu, Kaoru Kubota, Ryuzo Sekiguchi, Shigeru Nawano, Nagahiro Saijo, Yutaka Nishiwaki.
Abstract
We retrospectively investigated the clinical usefulness of fluorodeoxyglucose positron emission tomography (FDG-PET) for evaluation of patients with limited-disease small-cell lung cancer (LD-SCLC) diagnosed by conventional staging procedures. Sixty-three patients received whole body FDG-PET scans after routine initial staging procedures. The findings of FDG-PET scans suggesting extensive-stage disease were confirmed by other imaging tests or by the patient's clinical course. FDG-PET scan findings indicated distant metastases in 6 of 63 patients. Metastatic disease was confirmed in five of these six patients (8%, 95% confidence interval: 3-18%). FDG-PET scan also detected regional lymph node metastases even in nine patients (14%) in whom computed tomography images had been negative, including contralateral lymph node metastasis in three patients. FDG-PET scan detected additional lesions in patients diagnosed as having LD-SCLC by conventional staging procedures. The therapeutic strategies were changed in 8% of patients based on the results of FDG-PET. FDG-PET scan is recommended as an initial staging tool for patients with this disease.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17537538 DOI： 10.1016/j.lungcan.2007.04.001
Source DB: PubMed Journal: Lung Cancer ISSN： 0169-5002 Impact factor: 5.705